Sort
10,766 grants matching “checkpoint inhibitor”
Genetic screens for IR resistance
$534,340Stephen J Elledge · Dana-Farber Cancer Inst · U19 · FY2008 · AI
Genetic screens for IR resistance
$534,330Stephen J Elledge · Dana-Farber Cancer Inst · U19 · FY2009 · AI
Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction
$533,743Amy E Moran · Oregon Health & Science University · R37 · FY2023 · CA
Defining the role of mitochondrial injury in MEK inhibitor cardiotoxicity
$533,556Brian C Jensen · Univ Of North Carolina Chapel Hill · R01 · FY2023 · HL
Controllable In Vivo Genome Editing for Immune-Checkpoint Blockade in Solid Tumors
$533,472Sheng Tong · Rice University · R01 · FY2018 · EB
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
$533,414Yaguang Xi · University Of Georgia · R01 · FY2024 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
$533,358Anton Wellstein · Georgetown University · R01 · FY2021 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
$533,344Anton Wellstein · Georgetown University · R01 · FY2020 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
$533,211Anton Wellstein · Georgetown University · R01 · FY2018 · CA
Inhibition of Natural Killer Cell Function
$533,105Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Spatially precise radio-chemo-immunotherapy using antibody conjugates
$533,079Sunil J Advani · University Of California, San Diego · R01 · FY2023 · CA
Spatially precise radio-chemo-immunotherapy using antibody conjugates
$533,079Sunil J Advani · University Of California, San Diego · R01 · FY2025 · CA
Tissue Resident memory T cell responses to cancer
$532,934Mary J Turk · Dartmouth College · R01 · FY2021 · CA
Tissue Resident memory T cell responses to cancer
$532,934Mary J Turk · Dartmouth College · R01 · FY2020 · CA
Stanford Project 2
$532,885Calvin J Kuo · University Of California, San Francisco · U54 · FY2020 · CA
Biomarkers for acute interstitial nephritis in humans
$532,801Dennis G. Moledina · Yale University · R01 · FY2025 · DK
Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer
$532,240Tuan Vo-Dinh · Duke University · R01 · FY2020 · EB
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
$532,237Lily Yang · Emory University · R01 · FY2022 · CA
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
$532,237Lily Yang · Emory University · R01 · FY2023 · CA
Targeting GLI-dependent Transcription by GANT61 in Colon Cancer
$532,166Rebecca Boohaker · Southern Research Institute · R01 · FY2019 · CA
The Microbiome and Mucosal Immunity in Cervical Cancer Disparities
$531,423Adam Burgener · Case Western Reserve University · R01 · FY2024 · CA
Investigating mitochondrial networks as a critical determinant of response to antibody drug conjugates in advanced NSCLC
$531,379Aaron Elliott Lisberg · University Of California Los Angeles · R01 · FY2025 · CA
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
$531,356Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
$531,320Elias Sayour · University Of Florida · R01 · FY2023 · CA
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
$531,155Jin Xie · University Of Georgia · R01 · FY2022 · CA